摘要:
This invention relates to a 4-oxybenzopyran derivative of formula (I) wherein, R1 and R2 represent each independently a hydrogen atom, a C1-6 alkyl group or a phenyl group; R3 represents a hydroxyl group or a C1-6 alkylcarbonyloxy group; R4 represents a hydrogen atom, a C3-6 cycloalkyl group, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkylaminocarbonyl group, a di-C1-6 alkylaminocarbonyl group, an aryl group or a heteroaryl group; n represents an integer of 0-4; X represents —C(═O)NR7—, —NR8—, —NHC(═O)NH— or —S(O)2NH—; R5 represents a hydrogen atom or (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), or (l); R6 represents a hydrogen atom, a halogen atom, a nitro group or a cyano group; or a pharmaceutically acceptable salt thereof. And this invention also relates to an antiarrhythmic agent having the prolongation effect of the functional refractory period comprising said compound or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要:
The present invention relates to chroman derivatives of the formula (I): ##STR1## [wherin R.sup.1 represents a hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group, a C.sub.3-6 alkoxymethyl group, etc., R.sup.3 and R.sup.4 each independently represent a hydrogen atom, a C.sub.1-6 alkyl group, etc., R.sup.5 represents a hydroxyl group or a C.sub.1-6 alkylcarbonyloxyl group or forms a bond together with R.sup.5, R.sup.6 represents a hydrogen atom or forms a bond together with R.sup.5, R.sup.7 and R.sup.8 each independently represent a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-6 cycloalkyl group, a phenyl group, etc. n is 0 or an integer of 1, 2, 3 or 4, W represents a phenyl group, etc., X represents C.dbd.O, CH.sub.2, SO.sub.2, etc., Y represents NR.sup.17 (in which R.sup.17 represents a hydrogen atom, a C.sub.1-4 alkyl group, a phenyl group, etc.), etc., Z does not exist or represents CH.sub.2 or NR.sup.18 (R.sup.18 represents a hydrogen atom, a C.sub.1-4 alkyl group, or a phenyl group, etc.)] or their salts.
摘要:
A compound of the formula, ##STR1## or its pharmaceutically acceptable salt, and its preparation process and pharmaceutical compositions characterized by containing these compounds as effective ingredients.These compounds have strong antithrombotic activity, cardiotonic activity, vasodilator activity and anti-SRS-A activity, and are useful as prophylactic or therapeutic agents for various thrombotic affections, congestive heart failure, hypertension, asthma, immediate type allergy diseases and the like.
摘要:
A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, 2-propenyl, or straight chained or branched C.sub.1 -C.sub.4 alkyl; each of R.sub.2 and R.sub.3 which may be the same or different, is hydrogen, or straight chained or branched C.sub.1 -C.sub.3 alkyl; X is chlorine, or bromine; Y is hydrogen, halogen, nitro, amino, or --AR.sub.4 wherein A is oxygen, or sulfur, and R.sub.4 is hydroen, straight chained, branched or cyclic C.sub.1 -C.sub.8 alkyl, ##STR2## wherein R.sub.5 is hydrogen, or straight chained or branched C.sub.1 -C.sub.4 alkyl; and Ar is ##STR3## wherein each Z.sub.1 and Z.sub.2 which may be the same or different, is hydrogen, halogen, straight or branched C.sub.1 -C.sub.4 alkyl, or --OR.sub.6 wherein R.sub.6 is straight or branched C.sub.1 -C.sub.4 alkyl, and B is oxygen, sulfur, or --N.dbd.C-- (to form a quinoline or pyridine ring); or a pharamaceutically acceptable salt thereof.
摘要:
The present invention provides medicines for treating cardiac insufficiency which contain as an active ingredient indane derivatives of formula (I) wherein R1 represents hydrogen atom, nitro group, cyano group, C1-6 alkylcarbonylamino, R2 and R3 each independently represent C1-6 alkyl group, R4 represents hydroxyl group or C1-6 alkylcarbonyloxy group or represents a bond or oxygen atom together with R5, R5 represents hydrogen atom or represents a bond or oxygen atom together with R4, R6 represents hydrogen atom, hydroxyl group or NR7R8, n means 0 or an integer of 1 to 4, X represents C═O, CH2, SO2 or NR16, Y represents NR17 when X is C═O, CH2 or SO2 and represents C═O when X is NR16, Z is absent when Y represents NR17 or represents NR18 when Y is C═O, W represents aromatic groups or lactam rings, or pharmaceutically acceptable salt thereof.
摘要:
A benzimidazole derivative of the formula (I) or its salt: wherein A is a single bond or a C.sub.1-2 alkylene group (this alkylene group may optionally be substituted by a C.sub.1-4 alkyl group), R.sup.6 is a C.sub.1-4 alkyl group (this alkyl group may optionally be substituted by a phenyl group), B is a C.sub.2-3 alkylene group (this alkylene group may optionally be substituted by a C.sub.1-4 alkyl group), X is an oxygen atom, a sulfur atom or NR.sup.7 (wherein R.sup.7 is a nitro group, a cyano group or a C.sub.1-4 alkoxy group), each of R.sup.1 and R.sup.2 which are independent of each other, is a hydrogen atom, a halogen atom, a C.sub.1-4 alkyl group or a C.sub.1-4 alkoxy group, E is a C.sub.1-2 alkylene group (this alkylene group may optionally be substituted by a C.sub.1-4 alkyl group), R.sup.3 is a phenyl group (this phenyl group may optionally be substituted by a halogen atom, a C.sub.1-4 alkyl group or a C.sub.1-4 alkoxy group), a C.sub.1-4 alkoxy group or a benzyloxy group, each of R.sup.4 and R.sup.5 which are independent of each other, is a C.sub.1-4 alkyl group (this alkyl group may optionally be substituted by a phenyl group), D is a C.sub.1-2 alkylene group (this alkylene group may optionally be substituted by a C.sub.1-4 alkyl group), and Ar is a phenyl group.
摘要:
An organic bismuth derivative represented by formula (I) or its salt: �wherein X.sup.1 is YNR.sup.1 R.sup.2 (wherein Y is --SO.sub.2 -- or --C(O)--, R.sup.1 is a C.sub.3-6 alkyl group which have from 2 to 5 hydroxyl groups which may be protected, and R.sup.2 is a hydrogen atom, a C.sub.1-6 alkyl group or a C.sub.1-5 acyl group which may have from 1 to 5 hydroxyl groups which may be protected, or R.sup.1 and R.sup.2, together with each other, represent a C.sub.2-6 cyclic alkylene which may have from 1 to 4 hydroxyl groups which may be protected), and each of X.sup.2 and X.sup.3 is, independently of each other, a hydrogen atom, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a C.sub.1-4 alkylsulfonyl group, a C.sub.1-4 alkylcarbonyl group, a nitro group, a cyano group or the same as defined for X.sup.1 !.
摘要:
Pyrazole compounds of formula �1! and their tautomers and salts: ##STR1## (wherein R.sup.1 is an alkyl group, etc.; R.sup.2 is a carboxyl group, etc.; R.sup.3 is a halogen atom, an alkyl group, a phenyl group, etc.; R.sup.4, R.sup.5 and R.sup.6 each are a hydrogen atom, a halogen atom, etc.; R.sup.7 is a carboxyl group, a 5-tetrazolyl group, etc.; X is a nitrogen atom, etc.; Y and Z each are CH, a nitrogen atom, etc.; A and E each are a methylene group, etc.; D is a phenyl group, etc.; G is a covalent bond, etc.). The compounds of the invention have an antagonistic effect against angiotensin II and are useful for prevention and remedy of hypertension, congestive cardiac insufficiency, chronic renal insufficiency, aldosteronism, hyper-intraocular pressure, etc.
摘要:
An agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly, a TXA.sub.2 synthetase inhibitor, which comprises a pyridazinone compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof as an active ingredient. The pyridazinone compound (I) and pharmacologically acceptable salts thereof used in the present invention have prophylactic and therapeutic activities against TXA.sub.2 -mediated diseases, particularly a TXA.sub.2 synthetase inhibitory action and are useful as an agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly as TXA.sub.2 synthetase inhibitors.
摘要:
tris(substituted phenyl) bismuth compounds of formula (I) and pharmaceutically acceptable salts thereof are useful x-ray radiographic imaging agents: ##STR1## wherein X.sub.1, X.sub.2 and X.sub.3 are as defined in the specification.